$PDSB

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 31, 2026, PDS Biotechnology Corporation, a Delaware corporation (the “Company”), entered into a First Amendment to Promissory Note (the “Amendment”) with YA II PN, Ltd. (the “Holder”), which amends that certain Promi

Analysts from H.C. Wainwright and Deutsche Bank maintained Buy ratings on Spruce Biosciences (SPRB), PDS Biotechnology (PDSB), and BioNTech SE (BNTX). Price targets set at $150, $7, and $140 respectively. Current share prices are $63.40, $0.22, and $114.05. Analyst consensus for SPR and BNTX is Strong Buy, with upsides of 160.4% and 12.9% respectively.

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 2.05 Costs Associated with Exit or Disposal Activities. On August 6, 2026, the Board of Directors of PDS Biotechnology Corporation (the “Company”) approved a reduction in force as part of the Company’s efforts to align operating expenses with its strategic priorities and str

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 13, 2026, Lars Boesgaard submitted his resignation, effective as of September 12, 2026, as Chief Financial Office

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. PDS Biotechnology Corporation (the “Company”) held its 2026 annual meeting of stockholders on August 10, 2026 (the “Annual Meeting”). As previously disclosed, on June 15, 2026, the Board of Direct

PDS Biotechnology (PDSB) reported a $17.1M net loss for the six months ended June 30, 2026, with no product revenue. Operating expenses fell to $13.0M from $16.7M. Cash dropped to $5.6M from $26.7M at year-end 2025, and management said there is substantial doubt about its going concern. In June 2026, it redeemed $22.2M convertible debentures and issued a $6.0M 10% promissory note.

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PDS Biotech Reports Second Quarter 2026 Financial Results PRINCETON, N.J., August 13, 2026 -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted immunotherapies for canc

PDS Biotech said it will prioritize PDS0301, a tumor-targeted immunocytokine, and discontinue internal funding for the Phase 3 VERSATILE-003 trial of PDS0101, seeking partnerships or external funding instead. In Phase 2 data with the NCI for metastatic MSS/MSI? colorectal cancer, it reported 71% objective response at 6 months and 80% survival at 24 months. PDS0301 will move to a randomized Phase 2b. Shares were $0.2568, down 64.87%.

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 ef20076071_ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 PDS BIOTECHNOLOGY CORPORATION Common Stock (par value $0.00033 per share) Sales Agreement June 15, 2026 Yorkville Securities, LLC 1012 Springfield Avenue Mountainside, NJ 07092 B. Riley Securities, Inc. 299 Park Avenue, 21 st

$5.3 million Upfront with up to an Additional $5.8 million of Aggregate Gross Proceeds upon the Cash Exercise in Full of Warrants $5.3 million Upfront with up to an Additional $5.8 million of Aggregate Gross Proceeds upon the Cash Exercise in Full of Warrants ...